Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection
Phase of Trial: Phase I
Latest Information Update: 18 Jun 2015
At a glance
- Drugs H56IC (Primary) ; IC 31
- Indications Tuberculosis
- Focus Adverse reactions; First in man
- Sponsors Aeras
- 29 Oct 2013 New source identified and integrated: ClinicalTrials.gov record.
- 01 Jun 2013 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 17 Jan 2012 New trial record